<DOC>
	<DOCNO>NCT02139904</DOCNO>
	<brief_summary>This study patient malignant mesothelioma lung lining ( call pleura ) previous chemotherapy platinum-based regimen whose disease progress . Malignant pleural mesothelioma ( MPM ) aggressive , frequently drug resistant , incurable disease increase incidence UK worldwide . All patient MPM relapse follow first line chemotherapy present , standard treatment available patient second line set . The vinca alkaloid chemotherapy drug vinorelbine show promising activity single arm UK trial . However date , randomise evaluation vinorelbine mesothelioma second line set . In addition , trial look underlying molecular change mesothelioma may predict vinorelbine efficacy ; This might allow vinorelbine use patient chance benefit . Studies suggest vinorelbine require gene call BRCA1 ( show absent 38 % mesothelioma case ) order induce cell death mesothelioma . The VIM trial aim establish whether vinorelbine patient MPM help live long whether BRCA1 gene helpful select patient likely benefit treatment . Patients randomise ( 1:2 ) receive either active symptom control ( ASC ) ( supportive care deem necessary pain management exclude disease modify treatment ) ASC vinorelbine . Patients continue vinorelbine treatment evidence disease progression ( unacceptable toxicity drug patient withdrawal ) . If vinorelbine activity demonstrate , use result trial inform design future phase III trial .</brief_summary>
	<brief_title>Vinorelbine Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>1 . Confirmed histological diagnosis malignant pleural mesothelioma . The block 10 unstained slide available translational research 2 . Prior treatment firstline standard platinum doublet base chemotherapy 3 . Evidence disease progression accord CT scan 4 . Life expectancy ≥ 3 month 5 . ECOG performance status 02 6 . Men woman age 18 year 7 . Willing consent provide blood tissue translational research 8 . Measurable lesion modify RECIST 9 . Adequate organ function , include follow : Adequate bone marrow reserve : absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L , WBC &gt; 3 x 109/L , haemoglobin ≥ 100g/L , platelet ≥ 100 x 109/L ; adequate liver function : Bilirubin &lt; 1.5 x ULN AST/ALT 1.5 2.5 x ULN . 10 . Patients reproductive potential ( male female ) , sexually active duration trial drug washout period , prepare use two effective form contraception throughout participation trial least three month last dose vinorelbine . 11 . Patients must provide informed consent prior study specific procedure . 1 . Patients diagnosis second malignancy except prostate cervical cancer remission patient diagnosis basal cell carcinoma skin . 2 . Have receive treatment agent receive regulatory approval , within 30 day study entry . 3 . Are pregnant breastfeeding . 4 . Uncontrolled CNS disease . 5 . Known contraindication hypersensitivity vinorelbine vinca alkaloid constituent 6 . Any disease significantly affect absorption 7 . Previous significant surgical resection stomach small bowel 8 . Yellow fever vaccine within 30 day consent 9 . Previous vinca alkaloid chemotherapy 10 . Palliative radiotherapy within RECIST area 4 week prior baseline CT chest randomisation . 11 . Patients unable swallow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Mesothelioma</keyword>
	<keyword>Vinorelbine</keyword>
	<keyword>BRCA1</keyword>
</DOC>